Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation...

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Signal transducer and activator of transcription (STAT) proteins regulate gene expression by transducing signals from cytokines and growth factors.
• While STAT mutations are not found in human tumors, STAT1 and STAT5 activity is deregulated in various carcinomas.
• STAT1 and STAT5 possess a conserved SH2 domain essential for their activation and dimerization.

Purpose of the Study:

• To identify dual inhibitors targeting both STAT1 and STAT5 proteins.
• To screen a large database of natural products and natural product-like compounds for potential dual inhibitors.
• To investigate novel natural compounds for their inhibitory potential against STAT1 and STAT5.

Main Methods:

• Virtual screening using molecular docking to identify potential dual inhibitors.
• Molecular dynamics simulations of receptor-ligand complexes (STAT1-STOCK-1N-69677 and STAT5-STOCK-1N-69677) for 50 ns.
• Analysis of molecular interactions within the SH2 domains of STAT1 and STAT5.

Main Results:

• Compound STOCK-1N-69677 was identified as a potential dual inhibitor for STAT1 and STAT5.
• Molecular docking and dynamics simulations revealed conserved amino acid residues in the SH2 domain responsible for ligand stabilization.
• Detailed analysis of bonded and non-bonded interactions confirmed the binding of STOCK-1N-69677 to the SH2 domain.

Conclusions:

• Compound STOCK-1N-69677 shows promise as a dual inhibitor of STAT1 and STAT5.
• The SH2 domain is a key target for developing dual inhibitors of STAT1 and STAT5.
• This study provides a foundation for further development of natural product-based therapies targeting deregulated STAT signaling in cancer.